ERIS Lifesciences Ltd's Q4FY25 Quarterly Results

Result Summary

• ERIS Lifesciences Ltd reported a 22.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 40.2%.
• Its expenses for the quarter were down by 20.5% QoQ and up 49.3% YoY.
• The net profit decreased 8.4% QoQ and increased 29.5% YoY.
• The earnings per share (EPS) of ERIS Lifesciences Ltd stood at 5.2 during Q4FY25.

Financial Statments for Q4FY25

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

ERIS Lifesciences Ltd is a pharmaceutical company primarily engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company predominantly focuses on prescription-based products catering to therapeutic segments such as cardiovascular, diabetes management, gastroenterology, and dermatology. As a significant player in the pharmaceutical industry, ERIS Lifesciences is known for its strong product portfolio and its emphasis on chronic and lifestyle-related disorders. The company has consistently aimed at expanding its market presence through strategic partnerships, innovative product launches, and a robust distribution network. However, specific recent developments or strategic changes within the company are not detailed in the available data.

Revenue

In the fourth quarter of fiscal year 2025 (Q4FY25), ERIS Lifesciences Ltd reported a total income of ₹566.07 crores. This represents a decrease of 22.6% quarter-over-quarter (QoQ) from ₹731.67 crores in Q3FY25. When compared to the fourth quarter of the previous fiscal year (Q4FY24), there is a substantial year-over-year (YoY) increase of 40.2% from ₹403.80 crores. This pattern reflects notable fluctuations in revenue over the examined periods. The quarterly decline contrasts with the annual growth, indicating variances in the company's income generation across different quarters.

Profitability

The profit before tax for Q4FY25 was reported at ₹76.65 crores, marking a decline of 34.0% from the previous quarter's ₹116.16 crores. Relative to the same quarter last year, the profit before tax showed a marginal increase of 1.0% from ₹75.90 crores. The tax expenses for Q4FY25 highlight a reversal amounting to -₹2.99 crores, differing significantly from a tax outlay of ₹29.23 crores in Q3FY25 and ₹14.42 crores in Q4FY24. Consequently, the profit after tax for Q4FY25 amounted to ₹79.63 crores, which is 8.4% lower than the preceding quarter but 29.5% higher compared to the corresponding quarter of the previous year. These tax and profit figures illustrate the company's fluctuating tax liabilities and their impact on net profitability.

Operating Metrics

The earnings per share (EPS) for Q4FY25 were ₹5.20, reflecting a decrease of 14.8% from ₹6.10 in Q3FY25. When compared year-over-year, the EPS saw an increase of 8.3% from ₹4.80 in Q4FY24. These figures suggest variability in shareholder value across the observed periods. The total expenses in Q4FY25 were ₹489.42 crores, a decline of 20.5% from Q3FY25, yet an increase of 49.3% compared to Q4FY24. This indicates a significant reduction in costs in the recent quarter while reflecting a substantial rise from the previous year. These operating metrics provide an insight into the company's expense management and its effects on overall financial performance.